Bristol Myers Squibb Statement on Istodax® (romidepsin) Relapsed/Refractory Peripheral T-cell Lymphoma U.S. Indication
The Pharma Data
AUGUST 3, 2021
In 2011, Celgene Corporation, now a wholly owned subsidiary of Bristol Myers Squibb, received accelerated approval by the U.S. Based on this outcome, Bristol Myers Squibb made the decision to withdraw the PTCL indication from the U.S. senior vice president, Hematology Development, Bristol Myers Squibb.
52 
Let's personalize your content